Senate bill caps insulin costs at $35 a month for insured and uninsured Americans

What does this do?

Starting January 1, 2027, S 4512 would limit out-of-pocket insulin costs to $35 per month for people with private health insurance, with no deductible required before the cap applies. If the negotiated price of insulin is already below $35, the patient's cost would instead be capped at 25 percent of that negotiated price. A separate program would allow doctors' offices and pharmacies to provide insulin to uninsured patients for no more than $35 per month, with the federal government reimbursing providers for the difference between $35 and the actual cost.

Who does it affect?

The bill directly affects the roughly 8 million Americans who use insulin to manage diabetes, whether covered by an employer plan, a self-purchased plan, or no insurance at all. Health insurers, employers who provide health benefits, pharmacies, and doctors' offices would also need to change how they handle insulin pricing and billing.

Why does it matter?

Providers who choose to participate in the uninsured program would be barred from billing uninsured patients more than $35 and would rely on federal reimbursement to cover remaining costs. Insurers and employers would be required to restructure insulin cost-sharing arrangements so that deductibles no longer delay access to the cap.

What does it cost, and who pays?

The federal government would reimburse participating pharmacies and doctors' offices for the difference between the $35 patient charge and the actual cost of insulin provided to uninsured patients. Payments made by insured patients under the cap still count toward their annual deductible and out-of-pocket maximum.

Where does it stand?